Side-by-side financials for APRE and LLY. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | APRE | LLY |
|---|---|---|
| Market cap | - | $1.072 T |
| US-listed rank | - | #11 |
| Revenue (latest FY) | - | $65.18B |
| Net income (latest FY) | -$12.60M | $20.64B |
| Net margin | - | 31.7% |
| P/E (trailing FY) | - | 51.9 |
| SEC filings | 425 | 989 |
Full pages: Aprea Therapeutics, Inc. and ELI LILLY & Co, or browse the full rankings.